Skip to content

Efficacy and Safety of Tranexamic Acid for the Prevention of Postpartum Hemorrhage in High-risk Women Undergoing Vaginal Delivery

Efficacy and Safety of Tranexamic Acid for the Prevention of Postpartum Hemorrhage in High-risk Women Undergoing Vaginal Delivery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062464
Enrollment
Unknown
Registered
2022-08-08
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum hemorrhage

Interventions

A:Maternal intravenous injection of 1g of tranexamic acid after the umbilical cord is cut or clamped.
B:Maternal intravenous injection of normal saline after the umbilical cord is cut or clamped.

Sponsors

Tianjin Central Hospital of Gynecology Obstetrics
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
14 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Planned vaginal delivery; 2. Signed informed consent; 3. Patients with one or more PPH risk factors as follows; (1) Prenatal risk factors: 1) Parity>3; 2) BMI>=30 kg/m2; 3) Gestational diabetes; 4) Hydramnios; 5) Maternal age>=35 years or <18 years; 6) Uterine fibroids; 7) Multiple pregnancies; 8) Premature rupture of membranes; 9) Non-cephalic delivery; 10) History of uterine surgery ; 11) Placenta previa marginalis; 12) Anemia (Hb < 110g/ L); 13) The history of PPH; 14) Assisted reproductive technology; 15) Induced labor; (2) Perinatal risk factors: 1) Prolonged second stage of labor; 2) Prolonged third stage of labor; 3) Use of obstetric apparatus (fetal suction, forceps); 4) Matenal body temperature is above 38?; 5) Precipitate labour; 6) Placenta and fetal membranes retention which need to be cleared; 7) Placental adhesions and suspected implantation which require manual intervention. 8) Laceration of cervix and vagina; 9) Macrosomia; 10) Perineal trauma (laceration of grade II and above, episiotomy).

Exclusion criteria

Exclusion criteria: 1. Patients with drug contraindications for TXA; 2. A history of venous or arterial thrombosis (deep venous thrombosis; pulmonary embolism; angina, myocardial infarction, stroke and so on); thrombophilia; 3. Known cardiovascular,kidney or liver disease; autoimmune diseases; hematological system diseases and coagulation dysfunction; 4. Gestational hypertension, preeclampsia, HELLP syndrome, eclampsia; 5. History of epilepsy.

Design outcomes

Primary

MeasureTime frame
Incidence of postpartum hemorrhage,defined by blood loss >= 500 mL 24h after vaginal delivery.;

Secondary

MeasureTime frame
Mean blood loss 2 hours after delivery ;Incidence of severe postpartum hemorrhage,defined by blood loss >= 1000 mL 24h after vaginal delivery;The occurrence of potential mild adverse effects of TXA while in hospital,including nausea ,vomiting ,phosphenes and dizziness ; The occurrence of potential severe adverse effects of TXA 30 days after delivery. ;

Countries

China

Contacts

Public ContactChen Xu

Tianjin Central Hospital of Gynecology Obstetrics

chenxu2665@126.com+86 18920196555

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026